Abliva AB (publ) (ABLI.ST)
SEK 0.44
(0.23%)
SEK 0.44
(0.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 87.49 Million SEK | -52.4% |
| 2022 | 183.82 Million SEK | 212.01% |
| 2021 | 58.91 Million SEK | -60.89% |
| 2020 | 150.66 Million SEK | 1.46% |
| 2019 | 148.49 Million SEK | 28.78% |
| 2018 | 115.3 Million SEK | -3.99% |
| 2017 | 120.1 Million SEK | -33.54% |
| 2016 | 180.71 Million SEK | 3.31% |
| 2015 | 174.92 Million SEK | 33.26% |
| 2014 | 131.26 Million SEK | 47.2% |
| 2013 | 89.17 Million SEK | 24.71% |
| 2012 | 71.5 Million SEK | 111.41% |
| 2011 | 33.82 Million SEK | -19.77% |
| 2010 | 42.15 Million SEK | 273.43% |
| 2009 | 11.28 Million SEK | -8.49% |
| 2008 | 12.33 Million SEK | 306.63% |
| 2007 | 3.03 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 63.17 Million SEK | -27.8% |
| 2024 Q2 | 75.69 Million SEK | 19.83% |
| 2023 FY | 87.49 Million SEK | -52.4% |
| 2023 Q1 | 156.65 Million SEK | -14.78% |
| 2023 Q2 | 142.02 Million SEK | -9.34% |
| 2023 Q4 | 87.49 Million SEK | -19.73% |
| 2023 Q3 | 109 Million SEK | -23.25% |
| 2022 Q1 | 61.68 Million SEK | 4.7% |
| 2022 FY | 183.82 Million SEK | 212.01% |
| 2022 Q4 | 183.82 Million SEK | -9.74% |
| 2022 Q3 | 203.67 Million SEK | 11.54% |
| 2022 Q2 | 182.6 Million SEK | 196.03% |
| 2021 Q3 | 99.9 Million SEK | -45.42% |
| 2021 Q4 | 58.91 Million SEK | -41.02% |
| 2021 FY | 58.91 Million SEK | -60.89% |
| 2021 Q1 | 137.04 Million SEK | -9.04% |
| 2021 Q2 | 183.04 Million SEK | 33.56% |
| 2020 Q4 | 150.66 Million SEK | -7.27% |
| 2020 Q3 | 162.47 Million SEK | 1.3% |
| 2020 Q1 | 119.89 Million SEK | -19.26% |
| 2020 FY | 150.66 Million SEK | 1.46% |
| 2020 Q2 | 160.39 Million SEK | 33.78% |
| 2019 FY | 148.49 Million SEK | 28.78% |
| 2019 Q2 | 189.76 Million SEK | -7.27% |
| 2019 Q1 | 204.64 Million SEK | 77.48% |
| 2019 Q3 | 170.18 Million SEK | -10.32% |
| 2019 Q4 | 148.49 Million SEK | -12.75% |
| 2018 Q3 | 129.69 Million SEK | -10.46% |
| 2018 Q4 | 115.3 Million SEK | -11.09% |
| 2018 Q1 | 108.24 Million SEK | -9.88% |
| 2018 FY | 115.3 Million SEK | -3.99% |
| 2018 Q2 | 144.85 Million SEK | 33.82% |
| 2017 Q4 | 120.1 Million SEK | -3.02% |
| 2017 Q2 | 134.96 Million SEK | -12.86% |
| 2017 FY | 120.1 Million SEK | -33.54% |
| 2017 Q1 | 154.88 Million SEK | -14.29% |
| 2017 Q3 | 123.85 Million SEK | -8.24% |
| 2016 Q2 | 226.2 Million SEK | 33.25% |
| 2016 FY | 180.71 Million SEK | 3.31% |
| 2016 Q1 | 169.76 Million SEK | -2.95% |
| 2016 Q4 | 180.71 Million SEK | -6.35% |
| 2016 Q3 | 192.97 Million SEK | -14.69% |
| 2015 Q4 | 174.92 Million SEK | -8.47% |
| 2015 FY | 174.92 Million SEK | 33.26% |
| 2015 Q3 | 191.1 Million SEK | -19.86% |
| 2015 Q2 | 238.47 Million SEK | 21.27% |
| 2015 Q1 | 196.63 Million SEK | 49.8% |
| 2014 Q1 | 155.83 Million SEK | 74.75% |
| 2014 Q2 | 136.58 Million SEK | -12.35% |
| 2014 FY | 131.26 Million SEK | 47.2% |
| 2014 Q4 | 131.26 Million SEK | -1.71% |
| 2014 Q3 | 133.54 Million SEK | -2.23% |
| 2013 Q4 | 89.17 Million SEK | 51.37% |
| 2013 Q2 | 64.33 Million SEK | -3.11% |
| 2013 Q1 | 66.4 Million SEK | -7.14% |
| 2013 Q3 | 58.91 Million SEK | -8.43% |
| 2013 FY | 89.17 Million SEK | 24.71% |
| 2012 Q1 | 33.06 Million SEK | -2.25% |
| 2012 Q2 | 78.42 Million SEK | 137.19% |
| 2012 Q3 | 72.95 Million SEK | -6.98% |
| 2012 Q4 | 71.5 Million SEK | -1.98% |
| 2012 FY | 71.5 Million SEK | 111.41% |
| 2011 Q4 | 33.82 Million SEK | -5.75% |
| 2011 FY | 33.82 Million SEK | -19.77% |
| 2011 Q1 | 40.49 Million SEK | -3.95% |
| 2011 Q3 | 35.88 Million SEK | -8.91% |
| 2011 Q2 | 39.39 Million SEK | -2.72% |
| 2010 Q4 | 42.15 Million SEK | -2.49% |
| 2010 Q3 | 43.23 Million SEK | -5.78% |
| 2010 FY | 42.15 Million SEK | 273.43% |
| 2010 Q2 | 45.89 Million SEK | 190.87% |
| 2010 Q1 | 15.77 Million SEK | 39.74% |
| 2009 FY | 11.28 Million SEK | -8.49% |
| 2009 Q4 | 11.28 Million SEK | 0.0% |
| 2008 FY | 12.33 Million SEK | 306.63% |
| 2007 FY | 3.03 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Active Biotech AB (publ) | 44 Million SEK | -98.861% |
| Biovica International AB (publ) | 131.4 Million SEK | 33.414% |
| Cantargia AB (publ) | 223.71 Million SEK | 60.888% |
| CombiGene AB (publ) | 120.61 Million SEK | 27.454% |
| Cyxone AB (publ) | 43.65 Million SEK | -100.433% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -206.928% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -189.991% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -11.192% |
| Fluicell AB (publ) | 9.34 Million SEK | -836.82% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 75.095% |
| Mendus AB (publ) | 755.95 Million SEK | 88.425% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 37.766% |
| I-Tech AB | 152.44 Million SEK | 42.602% |
| Intervacc AB (publ) | 259.61 Million SEK | 66.296% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -160.398% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 68.61% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -336.6% |
| OncoZenge AB (publ) | 20.34 Million SEK | -330.182% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -40.274% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 86.611% |
| Lipum AB (publ) | 12.11 Million SEK | -622.535% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 26.13% |
| Ziccum AB (publ) | 14.97 Million SEK | -484.418% |
| BioArctic AB (publ) | 1.18 Billion SEK | 92.623% |
| Genovis AB (publ.) | 288.85 Million SEK | 69.709% |
| Camurus AB (publ) | 1.9 Billion SEK | 95.414% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 50.599% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -40.782% |
| Aptahem AB (publ) | 63.02 Million SEK | -38.832% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 82.368% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 88.566% |
| Kancera AB (publ) | 65.64 Million SEK | -33.295% |
| Saniona AB (publ) | 64.14 Million SEK | -36.412% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -65.139% |
| AcouSort AB (publ) | 34.51 Million SEK | -153.525% |
| Xintela AB (publ) | 18.39 Million SEK | -375.667% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 93.047% |
| Amniotics AB (publ) | 26.08 Million SEK | -235.425% |
| 2cureX AB (publ) | 16.62 Million SEK | -426.31% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -1339.839% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 95.396% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 91.405% |
| Biosergen AB | 7.2 Million SEK | -1115.095% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -108.535% |
| Corline Biomedical AB | 100.1 Million SEK | 12.593% |
| NextCell Pharma AB | 81.28 Million SEK | -7.641% |
| Nanologica AB (publ) | 77.42 Million SEK | -13.005% |
| LIDDS AB (publ) | 17.65 Million SEK | -395.605% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 88.49% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 93.751% |
| SynAct Pharma AB | 228.01 Million SEK | 61.626% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -226.94% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -303.168% |
| Alzinova AB (publ) | 123.18 Million SEK | 28.972% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -0.49% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 63.294% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -934.879% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -2.666% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -488.466% |
| Simris Alg AB (publ) | 174.55 Million SEK | 49.872% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 59.685% |